PRESS RELEASE
Kuala Lumpur, 28 October 2020 : Nexgram Biomedic unit Medical Brands Inc (MBI) inked Strategic Cooperation Head of Agreement (SCHOA) with Mcio BioMed Ltd (Mico BioMed) on 12 October, 2020, in mutual interest in an exclusive licensing agreement and/or forming a joint venture to (a) prepare On-Site solution for Covid-19 PCR test for MBI Contract Award using TRACVIRUS E-Cert platform (“CONTRACT-AWARD”), and (b) develop and operate retail medical devices distribution under the Mico BioMed name dedicated to selling Mico BioMed Veri-Q Prep & PCR machines, extraction, kits, PCR reagents, and compatible products especially for Covid-19 testing (collectively “Covid-19 Test Solutions” or “SOLUTION”) to consumers over the MBI Indonesia business unit.
The product was submitted to Indonesia authority under pandemic emergency use and import approval was obtained within 14 days.
MBI is medical devices distributor, with local subsidiaries and offices in Singapore, Malaysia and Indonesia. The company Indonesia subsidiary was awarded Covid-19 Test & E-Certification contract to service over 1,000,000 Indonesia labours, and connected to over 200 hospital and labs in Indonesia. MBI is a subsidiary of Nexgram Biomedic, a part of Nexgram Holdings Berhad (Nexgram Group).
Mico BioMed manufactures medical equipment. The Company develops and sells medical kits, ultra-fast labchip real time polymerase chain reaction equipment, ultrafast real time polymerase chain reaction labchips, and other products. Mico BioMed conducts businesses in South Korea.
This release was submitted earlier to relevant authorities and public announcement submissions system upon contract signing according to Listing Rules.
About Nexgram Biomedic Sdn Bhd
NEXGRAM BIOMEDIC GROUP is a global bio pharmaceutical company dedicate to develop new medical devices, drugs, and technologies in support of innovations in the medical field. The group subsidiaries include Medical Brands and Tri-G Technologies which distribute medical devices, Vaccines Lab which conduct clinical trial and vaccine distribution, Medic Data Science which develops Covid-19 screening test and vaccine record tracking App using electronic certificates (E-Certs) for real-time record checking in work, school and travel, Nmed Industries which trade, distribute and invest in medical device and personal protection equipment manufacturing, as well as Glove Alliance in medical and disposable nitrile gloves trading, contract manufacturing and distribution. To learn more about us, visit nexgrambiomedic.com
DISCLAIMER
PUBLIC DISCLOSED & FORWARD LOOKING STATEMENTS
The material disclosed was deem important and crucial to disclose immediately, and had been submitted to relevant authorities according to relevant Listing Rules and Regulations. As a matter of governance and duty to shareholders, the Group management does not guarantee authority review, perception, approval or intervention for such disclosure to be published in public listed company disclosure system or format, deem fit to the relevant officers, regulatory bodies, or equivalent.
The statements contained herein may contain certain forward-looking statements relating to the Group that are based on the beliefs of the Group’s management as well as assumptions made by and information currently available to the Group’s management. These forward-looking statements are, by their nature, subject to significant risks and uncertainties. These forward-looking statements include, without limitation, statements relating to the Group’s business prospects, future developments, trends and conditions in the industry and geographical markets in which the Group operates, its strategies, plans, objectives and goals, its ability to control costs, statements relating to prices, volumes, operations, margins, overall market trends, risk management and exchange rates.
When used herein, the words “anticipate”, “believe”, “could”, “estimate”, “expect”, “going forward”, “intend”, “may”, “ought to”, “plan”, “project”, “seek”, “should”, “will”, “would” and similar expressions, as they relate to the Group or the Group’s management, are intended to identify forward-looking statements. These forward-looking statements reflect the Group’s views at the time such statement were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules and regulations relating to any aspects of the Group’s business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, the actions and developments of the Group’s competitors and the effects of competition in the industry on the demand for, and price of, the Group’s products and services, various business opportunities that the Group may or may not pursue, the Group’s ability to identify, measure, monitor and control risks in the Group’s business, including its ability to manage and adapt its overall risk profile and risk management practices, its ability to properly price its products and services, seasonal fluctuations and factors beyond the Group’s control. Subject to the requirements of the Listing Rules, the Group does not intend to update or otherwise revise such forward-looking statements, whether as a result of new information, future events or otherwise. As a result of these and other risks, uncertainties and assumptions, forward-looking events and circumstances discussed herein might not occur in the way the Group expects, or at all. Accordingly, you should not place reliance on any forward-looking information or statements. All forward-looking statements herein are qualified by reference to the cautionary statements set forth in this section.